That quote clearly suggests that prior systemic chemotherapy is not helping anti-PDxx performance for patients. Obviously the systemic chemo left a lot damaged cells, and therefore extensive exposed PS thus subduing these patients' immune systems. It begs the question, what does Bavi do? It covers exposed PS thereby activating the patients' immune systems. Exactly why Bavituximab is such a valuable element for immunotherapy. I'm not promoting chemo involvement in Bavi treatments. We may not see it anymore. Chemo is, in fact, poison and also wreaks the patient's immune system.
It would be a gift to have our own immune systems identify and target diseases: foreign pathegens and domestic (self) like cancer. That seems to be where we are now just arriving in oncology. If we can get the recipes nailed down through combination work this will be a remarkable century for medicine.
Let's see what happens when Bavi and Durva are paired in these upcoming trials. The companies, PPHM and AZN, may already have dosing data, and more, on 18 patients, per ASCO. Through the upcoming I-O combo trials I'm expecting to see some evidence of the Brekken Effect, +200-300% RRs and more, like long term adaptive immunity to a cancer. Sounds like there will be several small open label I-O combo P1 trials producing patient data across a few different cancer indications. Certainly they'll be much faster than large P2 and P3 trials.
I like where we are heading with partnerships and collaborations in I-O combinations.
IMO
sunstar
Market Data 
Markets 
AI
